Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation

@article{Tzellos2007TopicalTA,
  title={Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation},
  author={Thrasivoulos George Tzellos and Dimitrios Kouvelas},
  journal={European Journal of Clinical Pharmacology},
  year={2007},
  volume={64},
  pages={337-341}
}
BackgroundLesions of cutaneous lupus erythematosus (CLE) are refractory to a wide range of topical or systemic therapies. The pathogenesis of CLE is multifactorial and polygenic, and many of its details remain unclear. However, immunologic evidence suggests the possible therapeutic use of tacrolimus and pimecrolimus. CLE is one of the most common dermatological autoimmune disorders worldwide, which includes systemic lupus erythematosus (SLE) with malar rash, subacute cutaneous lupus… Expand
Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus
TLDR
The two available compounds, pimecrolimus and tacrolimus, do not induce the skin atrophy characteristic of corticosteroids, and are well-tolerated, but differentially effective in the various subsets of CLE. Expand
Cutaneous lupus erythematosus: update of therapeutic options part II.
TLDR
Many treatment options exist for CLE, but not many are supported by evidence from randomized controlled trials. Expand
A case of herpes zoster during pimecrolimus use for the treatment of subacute cutaneous lupus erythematosus
TLDR
A herpes zoster case during pimecrolimus therapy in a patient with SCLE lesions which did not respond well to treatment is presented. Expand
Cutaneous lupus erythematosus: update of therapeutic options part I.
TLDR
Recent information on topical and first-line systemic treatment for cutaneous lupus erythematosus is described in detail while providing the reader with up-to-date information on efficacy, side effects, and dosage for the various agents. Expand
Treatment of cutaneous lupus erythematosus
TLDR
In patients with cutaneous lupus erythematosus (CLE) and mild skin involvement, local therapy consisting of topically applied pharmacological agents, e.g., topical/intralesional steroids, may be sufficient, and randomized controlled trials are necessary for the approval of new therapeutic strategies in CLE. Expand
Drugs for discoid lupus erythematosus.
TLDR
The included trials inadequately addressed the primary outcome measures of this review (percentage with complete resolution of skin lesions, percentage with clearing of erythema in at least 50% of lesions, and improvement in patient satisfaction/quality of life measures), as expected by Cochrane. Expand
Interventions for cutaneous disease in systemic lupus erythematosus.
TLDR
Assessment of the effects of interventions for cutaneous disease in SLE compared with placebo, another intervention, no treatment, or different doses of the same intervention found Methotrexate may be superior to placebo with regard to complete clinical response and chloroquine may make no difference or may decrease response. Expand
Chapter 41 – Skin
TLDR
This chapter provides a comprehensive approach to the diagnosis, management, and treatment of patients with cutaneous manifestations of LE, including malar rash and generalized acute cutaneous lupus erythematosus (LE). Expand
Rheumatic manifestations of skin disease
TLDR
New outcome measures, treatments, and unusual manifestations of cutaneous lupus, dermatomyositis, scleroderma, and rheumatoid arthritis are reviewed. Expand
Innovative management of lupus erythematosus.
TLDR
This article focuses on the management of discoid lupus erythematosus, subacute cutaneous lupuse, and systemic lupuses when the usual therapeutic arsenal such as oral antimalarial drugs and topical/oral steroids fail or provide insufficient treatment efficacy. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 31 REFERENCES
Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative.
TLDR
Tacrolimus ointment 0.1% may be an effective alternative in patients with severe resistant cutaneous manifestations in lupus erythematosus and had significant amelioration of their extensive photosensitive rash. Expand
Pimecrolimus 1% cream for cutaneous lupus erythematosus.
TLDR
It is suggested that pimecrolimus 1% cream could be an efficacious and safe treatment option for cutaneous lupus erythematosus. Expand
The cutaneous pathology of lupus erythematosus: a review
TLDR
Recent advances in the understanding of the cutaneous histopathology which correlates with the traditional forms of LE, along with certain novel LE subtypes, are the focus of this review. Expand
Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis.
TLDR
A good response was observed for facial erythematous lesions with edematous or telangiectatic changes in systemic LE and dermatomyositis and tacrolimus will become a new tool for managing the skin lesions of collagen diseases. Expand
Safety of Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis
TLDR
No data that suggest that TCI use increases the risk of malignancy is known, and independent oncology experts have concluded that reported lymphomas were not related toTCI use. Expand
Cutaneous lupus erythematosus: Understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies
TLDR
Clinical features of cutaneous lupus and recent genetic data that elucidate potential candidate genes for both cutaneouslupus erythematosus (CLE) and SLE are reviewed and promising experimental therapies based on these advances are reviewed. Expand
The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review
  • M. Rustin
  • Medicine
  • The British journal of dermatology
  • 2007
TLDR
Although it is important that clinicians are aware of the recent changes in product labelling, extensive clinical trials continue to show that tacrolimus ointment is well tolerated, and is generally an effective therapy for suitable patients with AD. Expand
Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings.
TLDR
Individuals who have SCLE skin lesions as a component of their presenting illnesses represent a distinctive subset (subphenotype) of LE that enjoys a good prognosis with respect to life-threatening systemic manifestations of LE. Expand
Optimal Use of Antimalarials in Treating Cutaneous Lupus Erythematosus
TLDR
The aim of this review is to discuss the many facets of antimalarials that will help clinicians optimally utilize these agents when treating cutaneous LE. Expand
Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus.
TLDR
The data suggest that pimecrolimus cream for discoid lupus erythematosus seems to be a safe and clinically effective option, however, this was an open and uncontrolled study, and double-blind, placebo-controlled studies are needed. Expand
...
1
2
3
4
...